Benzinga's Top #PreMarket Losers

Comments
Loading...
NPS Pharmaceuticals NPSP fell 10.70% to $29.20 in pre-market trading. The FDA has voted 8-5 in favor of NPS Pharmaceuticals' Natpara. Achillion Pharmaceuticals ACHN shares slipped 3.28% to $11.78 in pre-market trading after falling 3.87% on Friday. Cree CREE shares dipped 2.75% to $41.50 in pre-market trading. Goldman Sachs downgraded from Buy to Neutral and lowered the target price from $60 to $48. Symantec SYMC dropped 2.16% to $24.00 in pre-market trading. Analysts at RBC Capital downgraded Symantec from Outperform to Sector Perform. Gilead Sciences GILD shares fell 1.41% to $102.20 in pre-market trading after the company reported that it has signed licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its hepatitis C treatments in developing countries.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!